Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine ((18)F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.
Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine ((18)F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.
复制标题
DOI：
10.1016/j.juro.2016.09.117
复制
发表时间：
2017-03
期刊：
影响因子：
--
通讯作者：
Willoch F
中科院分区：
文献类型：
--
作者：
Bach-Gansmo T;Nanni C;Nieh PT;Zanoni L;Bogsrud TV;Sletten H;Korsan KA;Kieboom J;Tade FI;Odewole O;Chau A;Ward P;Goodman MM;Fanti S;Schuster DM;Willoch F
在前列腺癌初始治疗后经历生化复发的男性中灵敏地检测癌灶具有重要的临床意义，可能对后续治疗选择产生影响。我们描述了一个多中心的经验，有效性和安全性的正电子发射断层扫描/计算机断层扫描剂氟鹿昔洛韦（18 F）后生化复发。共有596例患者在4个临床试验机构接受了氟氯昔洛韦（18F）正电子发射断层扫描/计算机断层扫描。根据基线前列腺特异性抗原值对检出率进行分层。在143次扫描中，根据组织学参考标准评估诊断性能。受试者水平的氟氯昔洛韦（18F）正电子发射断层扫描/计算机断层扫描检出率为67.7%（403/595次扫描）。在前列腺/床和盆腔淋巴结区域分别检测到38.7%（599例中的232例）和32.6%（596例中的194例）的阳性结果。26.2%（155/591）的扫描发现盆腔外转移灶。基线前列腺特异性抗原（≤ 0.79 ng/ml）最低四分位数患者的受试者水平检出率为41.4%（53/128）。在这些患者中，13例仅累及前列腺/床，16例累及盆腔淋巴结而无远处疾病，24例有远处转移。氟草苷（18F）正电子发射断层扫描/计算机断层扫描对所有采样病变的阳性预测值为62.2%，前列腺外和前列腺/床受累的阳性预测值分别为92.3%和71.8%。氟鹿草碱（18 F）耐受性良好，重复给药后安全性特征未发生改变。Fluciclovine（18F）耐受性良好，能够在广泛的前列腺特异性抗原值范围内检测局部和远处前列腺癌复发。
Sensitive detection of cancer foci in men experiencing biochemical recurrence following initial treatment of prostate cancer is of great clinical significance with a possible impact on subsequent treatment choice. We describe a multisite experience of the efficacy and safety of the positron emission tomography/computerized tomography agent fluciclovine (18F) after biochemical recurrence. A total of 596 patients underwent fluciclovine (18F) positron emission tomography/computerized tomography at 4 clinical sites. Detection rate determinations were stratified by the baseline prostate specific antigen value. Diagnostic performance was assessed against a histological reference standard in 143 scans. The subject level fluciclovine (18F) positron emission tomography/computer tomography detection rate was 67.7% (403 of 595 scans). Positive findings were detected in the prostate/bed and pelvic lymph node regions in 38.7% (232 of 599) and 32.6% of scans (194 of 596), respectively. Metastatic involvement outside the pelvis was detected in 26.2% of scans (155 of 591). The subject level detection rate in patients in the lowest quartile for baseline prostate specific antigen (0.79 ng/ml or less) was 41.4% (53 of 128). Of these patients 13 had involvement in the prostate/bed only, 16 had pelvic lymph node involvement without distant disease and 24 had distant metastases. The positive predictive value of fluciclovine (18F) positron emission tomography/computerized tomography scanning for all sampled lesions was 62.2%, and it was 92.3% and 71.8% for extraprostatic and prostate/bed involvement, respectively. Fluciclovine (18F) was well tolerated and the safety profile was not altered following repeat administration. Fluciclovine (18F) is well tolerated and able to detect local and distant prostate cancer recurrence across a wide range of prostate specific antigen values.
登录
查看更多内容
影响因子：
4.9
作者：
Mari Aparici C;Seo Y
通讯作者：
Seo Y
影响因子：
6.6
作者：
Thompson, Ian;Thrasher, James Brantley;Tangen, Catherine M.
通讯作者：
Tangen, Catherine M.
影响因子：
23.4
作者：
Pokorny, Morgan R.;De Rooij, Maarten;Thompson, Leslie C.
通讯作者：
Thompson, Leslie C.
DOI：
10.1007/s00259-015-3078-6
发表时间：
2015-07-01
影响因子：
9.1
作者：
Ceci, Francesco;Uprimny, Christian;Virgolini, Irene J.
通讯作者：
Virgolini, Irene J.
影响因子：
10.6
作者：
Shepherd, Tony;Owenius, Rikard
通讯作者：
Owenius, Rikard